Clinical experience appears to show the benefit of SAMe and NR in individuals with a severe PRPS1 deficiency phenotype, or Arts syndrome, and we feel that these therapies in Arts syndrome patients should be considered. This evidence concerns the gene PRPS1 and Arts syndrome.